IGF2R and systemic sclerosis: Overall levels of IGF2R in SSc may be lower via two compounding mechanisms: reduced steady-state levels of Igf2r transcript, as well as the presence of systemic circulating autoantibodies capable of recognizing and targeting the IGF2R in SSc patients [40].